Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2009 - 2026)

Ionis Pharmaceuticals' Current Deferred Revenue history runs 18 years deep, the most recent figure standing at $69.2 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 1509.28% year-over-year to $69.2 million in Q1 2026; TTM through Mar 2026 was $69.2 million, a 1509.28% increase from a year earlier, with the FY2025 full-year figure at $73.8 million, down 6.62% from the prior year.
• Current Deferred Revenue retreated to $69.2 million in Q1 2026 per IONS's latest filing, from $73.8 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $204.8 million in Q3 2023 and bottomed at $4.3 million in Q1 2025.
• The 5-year median for Current Deferred Revenue is $91.4 million (2022), against an average of $94.1 million.
• Across the five-year window, Current Deferred Revenue slumped 96.7% in 2025 and jumped 1509.28% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $90.6 million in 2022, then soared by 66.85% to $151.1 million in 2023, then slumped by 47.73% to $79.0 million in 2024, then dropped by 6.62% to $73.8 million in 2025, then dropped by 6.18% to $69.2 million in 2026.
• Per Business Quant, the three latest IONS Current Deferred Revenue figures stand at $69.2 million (Q1 2026), $73.8 million (Q4 2025), and $77.0 million (Q3 2025).